Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results [Yahoo! Finance]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Yahoo! Finance
GABA-aminotransferase inhibitor that targets drug-resistant epilepsies. The news could influence both sentiment and future expectations. See our latest analysis for Ovid Therapeutics. The recent news follows Ovid's announcement of a sizable private placement and ongoing investor interest, hinting at fresh momentum. While the share price hasn't skyrocketed, positive trial results appear to be nudging sentiment higher. The 1-year total shareholder return of 0.6% reflects a market still in “show-me” mode, even after a more upbeat stretch over the last three months. If this latest milestone builds confidence, Ovid's long-term story could start to shift. If you're curious what else is attracting attention in healthcare innovation, it's a great time to explore new opportunities with our See the full list for free. With shares still trading well below analyst targets, investors are left to wonder: Is Ovid undervalued at today's levels, or has the market already factored in the expect
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical OfficerGlobeNewswire
- Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
OVID
Earnings
- 11/12/25 - Miss
OVID
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 11/7/25 - Form DEF
- OVID's page on the SEC website